For example, a recent meta-analysis of 11 large outcomes trials found that, in those aged 65 years or older, the cardiovascular and/or kidney outcomes benefits of GLP-1 RA or SGLT2i therapy were consistent with the effects seen in the overall trial population [266]
Now, with ever-advancing developments in the field, exciting news about future weight loss treatments is excelling at a rapid pace
Retatrutide Dosing Based on Phase 2 trial escalation schedules, a gradual titration is recommended to minimize gastrointestinal side effects
The deal would lower the price of GLP-1s Ozempic, Wegovy, and Zepbound to about $350 a month, a savings of about $700, for orders made through an online marketplace set to debut next year
"If taking medications that decrease appetite or insulin requirements, people with type 1 diabetes still must continue taking their long-acting insulin or using their insulin pump." Semaglutide, vomiting, and DKA: A case study In a 2023 case report, a person with type 1 arrived at an emergency room with ketoacidosis, after suffering nausea and vomiting attributed to taking Wegovy (semaglutide) prescribed by his endocrinologist for weight loss
Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy
